Gentian Diagnostics

Gentian Diagnostics is a Norway-based public in vitro diagnostics company that develops, manufactures, and commercializes immunochemistry reagents for use on automated clinical chemistry analyzers. Its core strategy is to convert clinically relevant biomarkers into high-throughput particle-enhanced turbidimetric immunoassays, enabling routine laboratory adoption of tests in kidney disease, inflammation, infection, heart failure, pancreatic disease, and veterinary medicine. The company markets established assays including Cystatin C, fCAL turbo, Canine CRP, and fPELA turbo, while advancing newer products such as GCAL and an NT-proBNP assay. Gentian operates from Moss, Norway with subsidiaries in the US and Sweden and a representative office in China, and sells both directly and through major global IVD partners. The business is revenue-generating and publicly traded on Oslo Børs.